Notably, in vivo blockade of the CXCR3 receptor significantly reduced the efficacy of IM + anti-VEGF therapy (Figure 6F), and substantially reduced the abundance of tumor-infiltrating CD8 T cells (Figures 6G and 6H). The gene discussed is CD8A; the disease is neoplasm.